BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 10905602)

  • 1. Autoantibodies associated with acute rejection after liver transplantation for type-2 autoimmune hepatitis.
    Duclos-Vallée JC; Johanet C; Bach JF; Yamamoto AM
    J Hepatol; 2000 Jul; 33(1):163-6. PubMed ID: 10905602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes.
    Klein R; Zanger UM; Berg T; Hopf U; Berg PA
    Clin Exp Immunol; 1999 Nov; 118(2):290-7. PubMed ID: 10540193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sera of children with hepatitis C infection and anti-liver-kidney microsome-1 antibodies recognize different CYP2D6 epitopes than adults with LKM+/HCV+ sera.
    Herzog D; Yamamoto AM; Jara P; Maggiore G; Sarles J; Alvarez F
    J Pediatr Gastroenterol Nutr; 1999 Nov; 29(5):551-5. PubMed ID: 10554122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of cytochrome P450 2D6-specific LKM-autoantibodies following liver transplantation for Wilson's disease -- possible association with a steroid-resistant transplant rejection episode.
    Lohse AW; Obermayer-Straub P; Gerken G; Brunner S; Altes U; Dienes HP; Manns MP; Meyer zum Büschenfelde KH
    J Hepatol; 1999 Jul; 31(1):149-55. PubMed ID: 10424295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased incidence of anti-LKM autoantibodies in a consecutive cohort of hepatitis C patients from central Greece.
    Dalekos GN; Makri E; Loges S; Obermayer-Straub P; Zachou K; Tsikrikas T; Schmidt E; Papadamou G; Manns MP
    Eur J Gastroenterol Hepatol; 2002 Jan; 14(1):35-42. PubMed ID: 11782573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new approach to cytochrome CYP2D6 antibody detection in autoimmune hepatitis type-2 (AIH-2) and chronic hepatitis C virus (HCV) infection: a sensitive and quantitative radioligand assay.
    Yamamoto AM; Johanet C; Duclos-Vallee JC; Bustarret FA; Alvarez F; Homberg JC; Bach JF
    Clin Exp Immunol; 1997 Jun; 108(3):396-400. PubMed ID: 9182882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.
    Mizutani T; Shinoda M; Tanaka Y; Kuno T; Hattori A; Usui T; Kuno N; Osaka T
    Drug Metab Rev; 2005; 37(1):235-52. PubMed ID: 15747502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of anti-LKM-1(anti-CYP2D6) by an enzyme-linked immunosorbent assay in adult patients with chronic liver diseases.
    Miyakawa H; Kikazawa E; Abe K; Kikuchi K; Fujikawa H; Matsushita M; Kawaguchi N; Morizane T; Ohya K; Kako M
    Autoimmunity; 1999; 30(2):107-14. PubMed ID: 10435724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in anti-LKM-1 autoantibody immunoreactivity to CYP2D6 antigenic sites between hepatitis C virus-negative and -positive patients.
    Kitazawa E; Igarashi T; Kawaguchi N; Matsushima H; Kawashima Y; Hankins RW; Miyakawa H
    J Autoimmun; 2001 Nov; 17(3):243-9. PubMed ID: 11712862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoantibodies and defined target autoantigens in autoimmune hepatitis: an overview.
    Dalekos GN; Zachou K; Liaskos C; Gatselis N
    Eur J Intern Med; 2002 Aug; 13(5):293-303. PubMed ID: 12144908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon therapy in LKM-1 positive patients with chronic hepatitis C: follow-up by a quantitative radioligand assay for CYP2D6 antibody detection.
    Duclos-Vallée JC; Nishioka M; Hosomi N; Arima K; Leclercq A; Bach JF; Yamamoto AM
    J Hepatol; 1998 Jun; 28(6):965-70. PubMed ID: 9672171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autoantibodies and autoantigens in autoimmune hepatitis: important tools in clinical practice and to study pathogenesis of the disease.
    Zachou K; Rigopoulou E; Dalekos GN
    J Autoimmune Dis; 2004 Oct; 1(1):2. PubMed ID: 15679907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A major CYP2D6 autoepitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens.
    Sugimura T; Obermayer-Straub P; Kayser A; Braun S; Loges S; Alex B; Lüttig B; Johnson EF; Manns MP; Strassburg CP
    Autoimmunity; 2002 Dec; 35(8):501-13. PubMed ID: 12765476
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders.
    Villalta D; Bizzaro N; Da Re M; Tozzoli R; Komorowski L; Tonutti E
    Autoimmunity; 2008 Feb; 41(1):105-10. PubMed ID: 18176872
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishment of a novel radioligand assay using eukaryotically expressed cytochrome P4502D6 for the measurement of liver kidney microsomal type 1 antibody in patients with autoimmune hepatitis and hepatitis C virus infection.
    Ma Y; Gregorio G; Gäken J; Muratori L; Bianchi FB; Mieli-Vergani G; Vergani D
    J Hepatol; 1997 Jun; 26(6):1396-402. PubMed ID: 9210629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CYP2D6 antibodies detected by quantitative radioligand assay and relation to antibodies to liver-specific arginase in patients with autoimmune hepatitis.
    Kimura M; Tatsumi KI; Tada H; Izumi Y; Kaneko A; Kato M; Masuzawa M; Ikemoto M; Yabusaki Y; Hidaka Y; Amino N
    Clin Chim Acta; 2002 Feb; 316(1-2):155-64. PubMed ID: 11750286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane.
    Muratori L; Parola M; Ripalti A; Robino G; Muratori P; Bellomo G; Carini R; Lenzi M; Landini MP; Albano E; Bianchi FB
    Gut; 2000 Apr; 46(4):553-61. PubMed ID: 10716687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKM-1 sera from autoimmune hepatitis patients that recognize ERp57, carboxylesterase 1 and CYP2D6.
    Komurasaki R; Imaoka S; Tada N; Okada K; Nishiguchi S; Funae Y
    Drug Metab Pharmacokinet; 2010; 25(1):84-92. PubMed ID: 20208391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Target proteins in human autoimmunity: cytochromes P450 and UDP- glucuronosyltransferases.
    Obermayer-Straub P; Strassburg CP; Manns MP
    Can J Gastroenterol; 2000 May; 14(5):429-39. PubMed ID: 10851284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.